852A

DRUG6 trials

Conditions

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaBarrett EsophagusBreast CancerCervical CancerChronic Lymphocytic LeukemiaEndometrial CancerHodgkin's Lymphoma

Phase 1

Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions

CompletedNCT00091689

PfizerMelanoma

Start: 2004-09-30End: 2006-01-31Updated: 2008-10-27

Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors

CompletedNCT00095160

Masonic Cancer Center, University of MinnesotaNeoplasms

Start: 2003-10-31End: 2006-01-31Target: 42Updated: 2017-11-29

Phase 2

Use of 852A in Metastatic Cutaneous Melanoma.

CompletedNCT00189332

PfizerMelanoma, Unresectable Metatstatic Cutaneous Melanoma

Start: 2005-02-28End: 2006-08-31Target: 28Updated: 2008-10-27

Study of Immune Response Modifier in the Treatment of Hematologic Malignancies

TerminatedNCT00276159

Masonic Cancer Center, University of MinnesotaAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia +3

Start: 2006-01-31End: 2008-11-30Updated: 2019-09-04

Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers

CompletedNCT00319748

Masonic Cancer Center, University of MinnesotaBreast Cancer, Cervical Cancer, Endometrial Cancer +1

Start: 2006-04-30End: 2008-12-31Updated: 2019-08-26

Unknown Phase

Pilot Study of Oral 852A for Elimination of High-Grade Dysplasia in Barrett's Esophagus

TerminatedNCT00386594

Rogers, B.H. Gerald, M.D.Barrett Esophagus

Start: 2006-10-31End: 2012-10-31Target: 10Updated: 2009-01-21

852A

Sponsors

Conditions

Phase 1

Phase 2

Unknown Phase